



HAL
open science

Primary Progressive Aphasia Associated With GRN Mutations: New Insights Into the Non-amyloid Logopenic Variant

Dario Saracino, Sophie Ferrieux, Marie Nogues-Lassiaille, Marion Houot, Aurélie Funkiewiez, Leila Sellami, Vincent Deramecourt, Florence Pasquier, Philippe Couratier, Jérémie Pariente, et al.

► To cite this version:

Dario Saracino, Sophie Ferrieux, Marie Nogues-Lassiaille, Marion Houot, Aurélie Funkiewiez, et al.. Primary Progressive Aphasia Associated With GRN Mutations: New Insights Into the Non-amyloid Logopenic Variant. *Neurology*, 2021, 97 (1), pp.e88-e102. 10.1212/wnl.0000000000012174 . hal-03281660

HAL Id: hal-03281660

<https://hal.science/hal-03281660>

Submitted on 14 Dec 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

PPA associated with <I>GRN</I> mutations: New insights into the non-amyloid logopenic variant

Author(s):

Dario Saracino, MD; Sophie Ferrieux; Marie Noguès-Lassiaille; Marion Houot, MSc; Aurélie Funkiewiez, PhD; Leila Sellami, MD; Vincent Deramecourt, MD, PhD; Florence Pasquier, MD, PhD; Philippe Couratier, MD, PhD; Jérémie Pariente, MD, PhD; Amandine Géraudie; Stéphane Epelbaum, MD, PhD; David Wallon, MD, PhD; Didier Hannequin, MD, PhD; Olivier Martinaud, MD, PhD; Fabienne Clot, PhD; Agnès Camuzat, MSc; Simona Bottani, MSc; Daisy Rinaldi, PhD; Sophie Auriacombe, MD; Marie Sarazin, MD, PhD; Mira Didic, MD, PhD; Claire Boutoleau-Bretonnière, MD, PhD; Christel Thauvin-Robinet, MD; Julien Lagarde, MD; Carole Roué-Jagot, MD; François Sellal, MD, PhD; Audrey Gabelle, MD, PhD; Frédérique Etcharry-Bouyx, MD, PhD; Alexandre Morin, MD; Cinzia Coppola, MD, PhD; Richard Levy, MD, PhD; Bruno Dubois, MD; Alexis Brice, MD, PhD; Olivier Colliot, PhD; Maria Luisa Gorno-Tempini, MD, PhD; Marc Teichmann, MD, PhD; Raffaella Migliaccio, MD, PhD; Isabelle Le Ber, MD, PhD on behalf of the The French research network on FTD/FTD-ALS

Corresponding Author:

Isabelle Le Ber

isabelle.leber@upmc.fr

Affiliation Information for All Authors: Dario Saracino, Sorbonne Université, Paris Brain Institute Institut du Cerveau ICM, Inserm U1127, CNRS UMR 7225, Reference Centre for Rare or Early Dementias, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Aramis Project Team, Inria Research Center of Paris, France; Sophie Ferrieux, Reference Centre for Rare or Early Dementias, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Marie Noguès-Lassiaille, Reference Centre for Rare or Early Dementias, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Marion Houot, Sorbonne Université, Paris Brain Institute Institut du Cerveau ICM, Inserm U1127, CNRS UMR 7225, Reference Centre for Rare or Early Dementias, IM2A, Centre of Excellence of Neurodegenerative Disease (CoEN), CIC Neurosciences, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Aurélie Funkiewiez, Reference Centre for Rare or Early Dementias, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris Brain Institute Institut du Cerveau ICM, FrontLab, Paris, France; Leila Sellami, Sorbonne Université, Paris Brain Institute Institut du Cerveau ICM, Inserm U1127, CNRS UMR 7225, Reference Centre for Rare or Early Dementias, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Vincent Deramecourt, Univ Lille, Inserm U1171, CHU Lille, DistAlz, LiCEND, CNR-MAJ, Lille, France; Florence Pasquier, Univ Lille, Inserm U1171, CHU Lille, DistAlz, LiCEND, CNR-MAJ, Lille, France; Philippe Couratier, CMRR Service de Neurologie, CHU de Limoges, 2 avenue Martin Luther King, 87 000 Limoges, France; Jérémie Pariente, Department of Neurology, Toulouse University Hospital, ToNIC, Toulouse NeuroImaging Centre, Inserm, UPS, University of Toulouse, France; Amandine Géraudie, Department of Neurology, Toulouse University Hospital, ToNIC, Toulouse NeuroImaging Centre, Inserm, UPS, University of Toulouse, France; Stéphane Epelbaum, Sorbonne Université, Paris Brain Institute Institut du Cerveau ICM, Inserm U1127, CNRS UMR 7225, Reference Centre for Rare or Early Dementias, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Aramis Project Team, Inria Research Center of Paris, France; David Wallon, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Department of Neurology and CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, Rouen, France; Didier Hannequin, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Department of Neurology and CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, Rouen, France; Olivier Martinaud, Rouen University Hospital, Department of Neurology, F 76000, Rouen, Normandie Univ, UNICAEN, PSL Research University, EPHE, INSERM, U1077, CHU de Caen Normandie,

Neuropsychologie et Imagerie de la Mémoire Humaine, 14000 Caen, France; Fabienne Clot, UF de Neurogénétique Moléculaire et Cellulaire, Département de Génétique, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Paris, France; Agnès Camuzat, Sorbonne Université, Paris Brain Institute Institut du Cerveau ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpêtrière, EPHE, PSL Research University, Paris, France; Simona Bottani, Sorbonne Université, Paris Brain Institute Institut du Cerveau ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpêtrière, Aramis Project Team, Inria Research Center of Paris, France; Daisy Rinaldi, Sorbonne Université, Paris Brain Institute Institut du Cerveau ICM, Inserm U1127, CNRS UMR 7225, Reference Centre for Rare or Early Dementias, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Sophie Auriacombe, CMRR Nouvelle Aquitaine / Institut des Maladies Neurodégénératives clinique (IMNc), CHU de Bordeaux Hôpital Pellegrin, Bordeaux, France; Marie Sarazin, Unit of Neurology of Memory and Language, GHU Paris Psychiatry and Neurosciences, University of Paris, Hôpital Sainte Anne, Paris, Université Paris-Saclay, CEA, CNRS, Inserm, BioMaps, Orsay, France; Mira Didic, Aix Marseille Univ, INSERM, INS, Inst Neurosci Syst, Marseille, Service de Neurologie et Neuropsychologie, APHM Hôpital Timone Adultes, Marseille, France; Claire Boutoleau-Bretonnière, CHU Nantes, Inserm CIC04, Department of Neurology, Centre Mémoire de Ressources et Recherche, Nantes, France; Christel Thauvin-Robinet, Centre de génétique, Hôpital d'Enfants, CHU Dijon Bourgogne, Dijon, France; Julien Lagarde, Unit of Neurology of Memory and Language, GHU Paris Psychiatry and Neurosciences, University of Paris, Hôpital Sainte Anne, Paris, Université Paris-Saclay, CEA, CNRS, Inserm, BioMaps, Orsay, France; Carole Roué-Jagot, Unit of Neurology of Memory and Language, GHU Paris Psychiatry and Neurosciences, University of Paris, Hôpital Sainte Anne, Paris, Université Paris-Saclay, CEA, CNRS, Inserm, BioMaps, Orsay, France; François Sellal, CMRR Département de Neurologie, Hôpitaux Civils, Colmar, INSERM U-1118, Université de Strasbourg, Faculté de Médecine, 67085 Strasbourg, France; Audrey Gabelle, CMRR, Département de Neurologie, CHU de Montpellier, Inserm U1061, Université de Montpellier i-site MUSE, Montpellier, France; Frédérique Etcharry-Bouyx, Department of Neurology, CMRR Angers University Hospital, Angers, France; Alexandre Morin, Sorbonne Université, Paris Brain Institute Institut du Cerveau ICM, Inserm U1127, CNRS UMR 7225, Reference Centre for Rare or Early Dementias, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Aramis Project Team, Inria Research Center of Paris, France; Cinzia Coppola, Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Naples, Italy; Richard Levy, Sorbonne Université, Paris Brain Institute Institut du Cerveau ICM, Inserm U1127, CNRS UMR 7225, FrontLab, Reference Centre for Rare or Early Dementias, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Bruno Dubois, Sorbonne Université, Paris Brain Institute Institut du Cerveau ICM, Inserm U1127, CNRS UMR 7225, FrontLab, Reference Centre for Rare or Early Dementias, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Alexis Brice, Sorbonne Université, Paris Brain Institute Institut du Cerveau ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Olivier Colliot, Sorbonne Université, Paris Brain Institute Institut du Cerveau ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpêtrière, Aramis Project Team, Inria Research Center of Paris, France; Maria Luisa Gorno-Tempini, Department of Neurology, Memory and Aging Center, University of California, San Francisco, CA, USA; Marc Teichmann, Sorbonne Université, Paris Brain Institute Institut du Cerveau ICM, Inserm U1127, CNRS UMR 7225, FrontLab, Reference Centre for Rare or Early Dementias, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Raffaella Migliaccio, Sorbonne Université, Paris Brain Institute Institut du Cerveau ICM, Inserm U1127, CNRS UMR 7225, FrontLab, Reference Centre for Rare or Early Dementias, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Isabelle Le Ber, Sorbonne Université, Paris Brain Institute Institut du Cerveau ICM, Inserm U1127, CNRS UMR 7225, FrontLab, Reference Centre for Rare or Early Dementias, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France.

Contributions:

Dario Saracino: Drafting/revision of the manuscript for content, including medical writing for content; Study concept or design; Analysis or interpretation of data

Sophie Ferrieux: Major role in the acquisition of data; Analysis or interpretation of data

Marie Noguès-Lassaille: Major role in the acquisition of data; Analysis or interpretation of data

Marion Houot: Analysis or interpretation of data

Aurélie Funkiewiez: Drafting/revision of the manuscript for content, including medical writing for content; Analysis or interpretation of data

Leila Sellami: Drafting/revision of the manuscript for content, including medical writing for content; Analysis or interpretation of data

Vincent Deramecourt: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Florence Pasquier: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Philippe Couratier: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Jérémie Pariente: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Amandine Géraudie: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Stéphane Epelbaum: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

David Wallon: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Didier Hannequin: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Olivier Martinaud: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Fabienne Clot: Drafting/revision of the manuscript for content, including medical writing for content; Analysis or interpretation of data

Agnès Camuzat: Drafting/revision of the manuscript for content, including medical writing for content; Analysis or interpretation of data

Simona Bottani: Drafting/revision of the manuscript for content, including medical writing for content; Analysis or interpretation of data

Daisy Rinaldi: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Sophie Auriacombe: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Marie Sarazin: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Mira Didic: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Claire Boutoleau-Brettonnière: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Christel Thauvin-Robinet: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Julien Lagarde: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Carole Roué-Jagot: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

François Sellal: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Audrey Gabelle: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Frédérique Etcharry-Bouyx: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Alexandre Morin: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Cinzia Coppola: Drafting/revision of the manuscript for content, including medical writing for content

Richard Levy: Drafting/revision of the manuscript for content, including medical writing for content

Bruno Dubois: Drafting/revision of the manuscript for content, including medical writing for content

Alexis Brice: Drafting/revision of the manuscript for content, including medical writing for content

Olivier Colliot: Drafting/revision of the manuscript for content, including medical writing for content; Analysis or interpretation of data

Maria Luisa Gorno-Tempini: Drafting/revision of the manuscript for content, including medical writing for content; Analysis or interpretation of data

Marc Teichmann: Drafting/revision of the manuscript for content, including medical writing for content

Raffaella Migliaccio: Drafting/revision of the manuscript for content, including medical writing for content; Analysis or interpretation of data

Isabelle Le Ber: Drafting/revision of the manuscript for content, including medical writing for content; Study concept or design; Analysis or interpretation of data

Number of characters in title: 85

Abstract Word count: 250

Word count of main text: 5123

References: 52

Figures: 3

Tables: 3

Supplemental: 1) STROBE Checklist 2) PRISMA Checklist 3) Co-authors agreements for inclusion of 3 new co-authors 4) Revised manuscript with tracked changes

Statistical Analysis performed by: Dario Saracino, MD, Sorbonne Université, Paris Brain Institute Institut du Cerveau ICM, Inserm U1127, CNRS UMR 7225, Reference Centre for Rare or Early Dementias, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Aramis Project Team, Inria Research Center of Paris,

France; Marion Houot, MSc, Sorbonne Université, Paris Brain Institute Institut du Cerveau ICM, Inserm U1127, CNRS UMR 7225, Reference Centre for Rare or Early Dementias, IM2A, Centre of Excellence of Neurodegenerative Disease (CoEN), CIC Neurosciences, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France.

Search Terms: [29] Frontotemporal dementia, [35] Dementia aphasia

Acknowledgements: We thank the DNA and cell bank of the ICM (ICM, Paris), Kathy Larcher (UF de Neurogénétique, Pitié-Salpêtrière Hospital, Paris), Sandrine Noël (UF de Neurogénétique, Pitié-Salpêtrière Hospital, Paris), and Isabelle David (UF de Neurogénétique, Pitié-Salpêtrière Hospital, Paris) for their technical assistance. The authors wish to thank Valerio Gargiulo for his support in the final editing of the manuscript.

Study Funding: The research leading to these results received funding from the Investissements d'avenir ANR-11-INBS-0011. This work was funded by the Programme Hospitalier de Recherche Clinique (PHRC) FTLD-exome (to ILB, promotion by Assistance Publique Hôpitaux de Paris), PHRC Predict-PGRN (to ILB, promotion by Assistance Publique Hôpitaux de Paris). The funding source had no role in study design, data analysis or interpretation, writing or decision to submit the report for publication.

Disclosures: The authors report no disclosures relevant to the manuscript.

ABSTRACT

Objective. To determine relative frequencies and linguistic profiles of primary progressive aphasia (PPA) variants associated with progranulin (*GRN*) mutations, and study their neuroanatomical correlates.

Methods. PPA patients carrying *GRN* mutations (PPA-*GRN*) were selected amongst a national prospective research cohort of 1,696 frontotemporal dementia (FTD) patients, including 235 patients with PPA. All PPA patients with amyloid-positive CSF biomarkers were excluded. In this cross-sectional study, speech/language and cognitive profiles were characterized with standardized evaluations, and grey matter (GM) atrophy patterns using voxel-based morphometry. Comparisons were performed with controls, and sporadic PPA patients.

Results. Among the overall population of 235 patients, 45 (19%) carried *GRN* mutations. We studied 32 of these and showed that logopenic PPA (lvPPA) was the most frequent linguistic variant (13, 41%), followed by non-fluent/agrammatic (nfvPPA: 9, 28%) and mixed forms (8, 25%). Semantic variant was rather rare (2, 6%). LvPPA patients, qualified as non-amyloid-lvPPA, presented canonical logopenic deficit. Seven out of 13 had a pure form, six showed subtle additional linguistic deficits not fitting criteria for mixed PPA, hence labelled as “logopenic-spectrum variant”. GM atrophy primarily involved left posterior temporal gyrus, mirroring neuroanatomical changes of amyloid-positive-lvPPA. NfvPPA patients presented agrammatism (89%) rather than apraxia of speech (11%).

Conclusions. This study shows that most frequent PPA variant associated with *GRN* mutations is non-amyloid lvPPA, preceding nfvPPA and mixed forms, and illustrates that language network may be affected at different levels. *GRN* testing is indicated for PPA patients, whether familial or sporadic. This finding is important for upcoming *GRN* gene-specific therapies.

KEYWORDS

Primary progressive aphasia, frontotemporal dementia, frontotemporal lobar degeneration, genetics, logopenic variant PPA, progranulin (*GRN*), *C9orf72*.

DISCLOSURE

The authors report no disclosures relevant to the manuscript.

INTRODUCTION

Primary progressive aphasia (PPAs) are rare neurodegenerative disorders divided into three main clinical variants^{1,2}. The non-fluent/agrammatic variant (nfvPPA, formerly progressive non-fluent aphasia, PNFA) is characterized by disrupted, effortful language production, with agrammatism and apraxia of speech (AOS). The semantic variant (svPPA, formerly semantic dementia, SD) is dominated by anomia, conceptual knowledge and language comprehension deficits. Patients with logopenic variant (lvPPA) feature impairment of phonological working memory with single-word retrieval, sentence repetition deficits, and phonological errors. Those variants show characteristic neuroanatomical profiles involving left inferior frontal gyrus in nfvPPA, anterior temporal lobe in svPPA, and temporo-parietal junction in lvPPA³. NfvPPA and svPPA are predominantly associated with frontotemporal lobar degeneration (FTLD) with TAU or TDP-43 neuronal inclusions^{4,5}. Most lvPPA cases are reported to be associated with amyloid pathology⁵⁻¹².

GRN and *C9orf72*, the most prevalent FTD genes, are predominantly associated with behavioral variant of FTD (bvFTD) and, much more rarely, with a PPA phenotype¹³⁻¹⁸. The description of case-reports suggested that “genetic PPA” might have specific language and cognitive profiles^{16,19-21}. Moreover, defining their linguistic spectrum in large cohorts, and depicting specific profiles which may deserve appropriate genetic testing, would be of utmost importance in light of upcoming therapies. For this purpose, we aimed to comprehensively characterize the linguistic and cognitive profiles, and the patterns of grey matter (GM) atrophy of PPA associated with *GRN* mutations in a series of 32 patients, offering the opportunity to analyze homogeneous groups with highly predictable pathology, and potentially link specific molecular dysfunctions with clinical phenotypes.

MATERIALS AND METHODS

Selection of patients

The patients included in this study were prospectively enrolled in a clinico-genetic research cohort from 1996 to 2018 by neurologists of tertiary referral centers for neurodegenerative dementias, FTD and PPA, from 12 French university hospitals contributing to a national research network (Inserm RBM 02-59). All centers applied similar standardized evaluations and diagnostic procedures. Behavioral changes were evaluated using a scale derived from Frontal behavioral scale, the Frontal Behavioral Inventory and the Neuropsychiatric Inventory integrating the main elements of frontal syndrome (including apathy, disinhibition, hyperorality, stereotyped/ritualistic behaviors, emotion/affects), with the main caregiver and the patient.^{15,22,23} Cognitive and speech/language deficits were evaluated with semi-standardized protocols, whose scales are described below, by neuropsychologists and speech-language pathologists specialized in neurodegenerative dementias and PPA. Patients were also evaluated by neuroimaging procedures (brain MRI and/or SPECT and/or FDG-PET), and by CSF biomarkers in more recent cases. Biological samples were collected for genetic analyses and progranulin plasma dosage. Diagnoses were based on international diagnostic criteria^{2,23}.

During this period, a total of 1,696 patients with FTD or PPA were evaluated with these procedures, including 1,103 (65.0%) patients presenting bvFTD, 292 (17.2%) bvFTD associated with amyotrophic lateral sclerosis (FTD-ALS), 235 (13.8%) PPA, 39 (2.4%) progressive supranuclear palsy, and 27 (1.6%) corticobasal syndrome (CBS). Among the 1,696 patients, 162 carried pathogenic *GRN* mutations, 45 of whom received a diagnosis of PPA (PPA-*GRN*) based on investigations detailed below (Figure 1). Of note, 330 of 1,696 patients carried a *C9orf72* expansion, but only seven received a diagnosis of PPA.

In the context of the present investigation, a team of neurologists (RM, LS, DS), speech-language pathologists (SF, MNL), and a neuropsychologist (AF), from the French reference center on FTD

and PPA, reviewed the clinical data and scales of the 45 PPA-*GRN* patients. They independently validated the final diagnosis and variant classification based on current international criteria². MRI and/or functional neuroimaging were visually reviewed to confirm the PPA-consistent neuroimaging pattern. Notably, eight patients investigated before the definition of lvPPA³ were reclassified according to current criteria when possible (n=6), or excluded when not as a result of insufficient data to establish the variant (n=2). Other exclusion criteria were: CSF biomarkers consistent with Alzheimer's disease (AD) co-pathology (n=2), non-French native language (n=1), too severely compromised language at first evaluation (n=4) or incomplete language/cognitive evaluations (n=4) to formally diagnose a PPA variant at onset. CSF biomarkers were considered in favor of AD according to the following cut-offs: A β ₁₋₄₂ peptide below 500 pg/mL, total Tau protein above 450 pg/mL and phosphorylated Tau (P-Tau) above 60 pg/mL. In case of discordant results, the following cut-offs were applied: Tau/A β ₁₋₄₂ \geq 1.15 and P-Tau/A β ₁₋₄₂ \geq 0.21, according to manufacturer's instructions (ELISA kit, Innogenetics).

At the end of this selection process, 32 patients with *GRN*-related PPA were included in this study. Notably, AD pathology was excluded for 24/32 (75%) by CSF biomarkers. CSF was not obtained for eight carriers, among whom only three had lvPPA. The 32 PPA patients were kept in the study, as demographic and clinical characteristics were similar in both groups (with or without CSF), especially for executive functions and episodic memory (Supplemental data available from Dryad, Table e-1, <https://doi.org/10.5061/dryad.x3ffbg7hr>). The list of *GRN* mutations is provided in Table e-2. After their inclusion, the patients have been clinically evaluated in the context of their usual neurological follow-up.

Speech/language assessments

Speech and language evaluations

Speech/language deficits in the 32 PPA patients were assessed by speech-language pathologists specialized in neurodegenerative dementias. The performed tests are shown in Table e-3. Detailed speech/language evaluations were based on the Boston Diagnostic Aphasia Examination–French version (BDAE/HDAE-F)²⁴ (n=26 patients) or/and the Montreal-Toulouse protocol for examination of aphasia (MT86)²⁵ (n=18). Twelve had both batteries. Briefly, these scales evaluate motor speech production, grammar, single-word and sentence comprehension, repetition of words and sentences of increasing length and grammatical complexity, knowledge of objects/people, reading, spelling, and writing skills. Speech/language assessment also evaluated oral confrontation naming using the DO80 Picture-Naming Test²⁶, buccofacial praxis¹¹, phonological and semantic fluencies²⁷. The Pyramid and Palm-Tree Test (PPTT) or BECS-GRECO semantic battery²⁸ were performed in the patients who showed semantic impairment in previous batteries.

Spontaneous speech was elicited by means of a semi-structured interview, followed by the Cookie Theft picture description from BDAE. The patients' speech was scored at the time of the test by the speech-language pathologists. Written transcriptions were available for all patients. The verbal output was analyzed with respect to its production rate and the possible presence of word-finding pauses, phonological errors and “*conduites d'approche*” (i.e., repetitive effortful production of syllables and phonemes to approximate the target word)²⁹. The dissociation between single-word retrieval difficulties in spontaneous speech and naming (DO80 confrontation naming test) was signaled whenever present. Phonological errors in spontaneous speech and naming tasks were transcribed. Additionally, the rate of phonological errors in the confrontation naming task was calculated (as well as for other types of errors, such as verbal and semantic paraphasias, neologisms, periphrases, lack of response).

Grammaticality was evaluated by assessing the appropriateness of syntactic elaboration during spontaneous speech, referring to the scale proposed by Leyton *et al.* (2011)¹⁰. Agrammatism was defined by the presence of a “frank” impairment in grammar/syntax (corresponding to “definite”

or “severe” grade). To assess grammaticality in language reception, we referred to the performances in sentence comprehension tasks in BDAE and/or MT86. AOS was diagnosed in the presence of effortful, groping speech, with inconsistent phonemic substitutions or distortions due to inaccurate articulation, and difficulty with initiating utterances, as defined by Gorno-Tempini *et al.* (2011)². Auditory-verbal working memory was evaluated using forward and backward digit span tests (see below). Finally, the global severity of deficits in spontaneous/conversational speech was scored from 0 (no usable speech or auditory comprehension) to 5 (subjective difficulties not apparent to the listener) following BDAE recommendations (Table e-4).

Criteria fulfilment and aphasia classification

The diagnosis of nfvPPA, svPPA, or lvPPA was validated in patients strictly fulfilling the current criteria for one of these variants but not the others². The patients were diagnosed as “mixed PPA” when the criteria for more than one variant were met, and as “unclassifiable PPA” when not meeting criteria for any specific PPA variants^{6,7}. In order to thoroughly describe the linguistic spectrum of lvPPA in *GRN* patients, we labelled those without any additional signs of other variants as “pure lvPPA”, and some meeting canonical lvPPA criteria with very mild additional signs as “lvPPA+”. “LvPPA+” patients presented all the elements for lvPPA diagnosis with mild other features not allowing to classify them as mixed PPA.

Neuropsychological evaluations

All cognitive domains other than language were evaluated with a semi-standardized battery²², in order to investigate the presence of additional cognitive impairments (Table e-3).

Comparisons between PPA-*GRN* and sporadic PPA patients

We compared PPA-*GRN* patients with two groups of sporadic PPA patients (11 lvPPA and 9 nfvPPA patients) who did not carry any FTD-causative mutations and underwent the same diagnostic workup. The 11 lvPPA patients had a CSF profile in favor of underlying AD (lvPPA-AD). We compared demographic characteristics, speech/language, neuropsychological scores, and clinical symptoms between groups according to their PPA variant using Fisher's exact test for categorical variables, because of small frequencies. Wilcoxon rank-sum test was employed for numerical variables, since the continuous variables were not Gaussian. Correction for multiple testing was handled with the Benjamini-Hochberg method. Statistical analyses were performed using R4.0.3 (Vienna, Austria).

GM atrophy in *GRN* patients with lvPPA (lvPPA-*GRN*)

We analyzed brain 3D-T1-weighted MRI sequences available for eight lvPPA-*GRN* patients. The mean delay between the clinical evaluation and the brain MRI was ≤ 6 months. Their demographic and clinical data were similar to those of all lvPPA-*GRN* patients of this study, so as to ensure they were representative of the entire group (Table e-5). They were compared to 20 controls with similar demographic characteristics, and to 11 lvPPA-AD patients.

VBM analyses were performed using the *t1-volume* pipeline of Clinica (<http://www.clinica.run>), a wrapper of the segmentation, run Dartel, and normalize to Montreal Neurological Institute (MNI) space routines implemented in Statistical Parametrical Mapping (SPM). After the unified segmentation procedure, a group template was created using Dartel, and the Dartel-to-MNI method was then applied, incorporating the native space images into the MNI space. For group analyses, we used two-sample t-tests with age at MRI and gender as confounding covariates. The following set of contrasts was applied: lvPPA-*GRN* vs controls; lvPPA-AD vs controls; lvPPA-*GRN* vs lvPPA-AD. The statistical threshold was set at $p < 0.05$, corrected at the peak-level for family-wise error (FWE). The Neuromorphometrics atlas (www.neuromorphometrics.com) was

employed to identify anatomical regions with significant differences. To validate our findings by means of a complementary approach, we also analyzed cortical thickness profiles in lvPPA-*GRN* patients with the FreeSurfer software (Supplemental data, available in Dryad).

Literature review

Finally, to place our study in the context of the existing literature, and to get further insights in previously published PPA-*GRN* phenotypes, we performed an extensive review of the literature (DS and ILB). Our PubMed search used the terms: ((*GRN* OR *PGRN* OR progranulin) OR (Frontotemporal lobar degeneration AND genetics) AND (PPA OR Primary Progressive Aphasia). A total of 190 articles were found, published between 2006 (year of *GRN* identification) and 2020. In order to determine PPA-*GRN* frequencies within PPA or *GRN* patient cohorts, we selected cohort studies based on the following inclusion criteria: i) identification of *GRN* mutations with validated pathogenicity, ii) PPA diagnosis based on fulfillment of consensus criteria, and iii) cohort including at least 30 PPA patients or *GRN* carriers. This led to the inclusion of 8 cohort studies, from which we extracted essential measures of frequency (number of PPA-*GRN* cases out of total number of patients). In order to characterize the phenotypes of previously published PPA-*GRN*, we selected case reports and small case series fulfilling the following criteria: i) identification of *GRN* mutations of proven pathogenicity, ii) accurate descriptions of individual PPA phenotypes at onset and during follow-up, and iii) availability of the scores of formal speech/language evaluations. Notably, patients with mixed bvFTD-PPA phenotype at onset were excluded. We therefore encompassed 12 studies (including one published in 2003 identified through cross-referencing), comprehensively describing 23 PPA-*GRN* patients. For each of them, we extracted essential clinical information and verified the fulfillment of criteria of each PPA variant.

Standard protocol approvals, registrations and patient consents.

The ethics committee of Paris-Necker Hospital approved the research study (Project RBM 02-59).

All patients provided written informed consent before their inclusion.

Data availability policy

All relevant data are reported in the article. The raw data supporting the findings of this study are available from the corresponding author upon reasonable request.

RESULTS**Description of the PPA-GRN population**

Among the overall population of 235 PPA patients, 45 (19%) carried *GRN* mutations, of whom 32 (14%) were included in this study. Besides, the frequency of PPA phenotype among the 162 *GRN* carriers was estimated at 20% (32/162) or at 28% (45/162).

The demographic, clinical, linguistic and cognitive characteristics of the 32 patients are presented in Table 1, 2 and Table e-6. All were Caucasian. Their median age at onset was 62 years (interquartile range, IQR: 59.0, 63.3). Notably, only 26 (81%) had a positive family history (Table 1). Patients were at an early stage of the disease, as reflected by the short median disease duration (DD) (2.0 years; IQR: 1.5, 2.5) and the median aphasia severity score of 3.0 at the first evaluation. All signs/symptoms occurring afterwards, during disease progression, are detailed in Table 1.

Linguistic characteristics in PPA-GRN patients

A canonical PPA variant was diagnosed in 24 patients at their first evaluation (Figure 2). Overall, lvPPA was the most frequent variant (41%, 13/32 cases), followed by nfvPPA (28%, 9/32), and mixed PPA (25%, 8/32). SvPPA was much less frequent (6%, 2/32). None had “unclassifiable PPA”. The eight patients diagnosed with mixed PPA fulfilled the criteria of more than one variant.

Nevertheless, the complexity of their phenotype was not due to a longer DD (2 ± 0.8 years), which was similar to that of the entire cohort (2.2 ± 0.5 years).

Specific profiles emerged from in-depth analysis of the linguistic deficits of each patient, presented in Table e-6. *LvPPA-GRN* patients presented sparse spontaneous speech, marked by word-finding difficulties, incomplete sentences, prolonged pauses without motor speech deficit. Most patients exhibited sentence-level processing deficit (repetition and comprehension of long sentences), contrasting with preserved processing at the single-word level. Seven (22%) had “pure *lvPPA*” while six had “*lvPPA+*”, with co-occurrence of a mild articulatory disorder ($n=1$ case), and/or syntax oversimplification ($n=3$), and/or semantic impairment ($n=5$). Illustrative case-reports of “pure *lvPPA*” (patient #25) and “*lvPPA+*” (#02) are described in Supplemental data (available in Dryad). At group level, the profile of *lvPPA-GRN* was indistinguishable from the sporadic *lvPPA-AD* patients’ one (Table e-7).

Agrammatism prevailed in most (8/9) *nfvPPA* patients whereas AOS was the predominant presentation in only one case (#04). Notably, *nfvPPA* patients had slightly better performances in overall cognitive functioning and verbal memory than the global cohort (Table 2). Language and cognitive scores did not significantly differ between *nfvPPA-GRN* and sporadic *nfvPPA* patients (Table e-8). As the disease progressed, 22% of *nfvPPA-GRN* patients evolved to a CBS.

Eight patients with mixed PPA presented varying degrees of reduced speech output and word-finding difficulties with pauses. Confrontation naming and repetition of long sentences were impaired in all, and almost all exhibited phonological errors in spontaneous speech/naming. These logopenic/phonological impairments co-occurred with semantic deficits (5/8 patients) and/or grammar production and reception deficits (6/8).

Progression of PPA-GRN

All the patients have been clinically followed up in the context of their usual neurological care. Twelve patients also underwent one to three complete standardized speech/language assessments during their clinical follow-up.

Disease progression in PPA-GRN patients was remarkably severe and rapid (Table 1). The mean DD at complete mutism was 5.0 ± 1.3 years. Eight died after a mean DD of 7.3 ± 1.2 years, in line with the short survival of GRN patients. Fourteen were lost to follow-up after a mean DD of 3.9 ± 1.4 years, and 10 were still being followed up at the time of the study (5.6 ± 1.7 years).

During disease progression, all patients secondarily developed overt frontal disturbances. A cognitive executive syndrome was present in almost all patients at follow-up (31/32), and prevailed over behavioral impairment (18/32). More than half of patients subsequently developed a parietal syndrome. This could be likely related to the fast propagation of lesions to anterior frontotemporal and posterior parietal regions in GRN disease. A paradigmatic case description from our series exemplifies this progression pattern (Supplemental data). The broadening of the clinical syndrome during disease evolution led to the formulation of secondary diagnoses, later fulfilling criteria for bvFTD (n=16) or for CBS (n=3) (Table e-6).

Neuroanatomical changes in lvPPA-GRN

LvPPA-GRN patients showed significant atrophy in the left middle temporal (MT) and posterior orbital gyri compared to controls ($p < 0.05$, FWE correction) as illustrated in Figure 3A. Cortical thickness analyses were concordant with these results despite showing more extended prefrontal and left temporo-parietal junction involvement, likely due to the less stringent correction adopted (Figure e-1).

LvPPA-AD patients showed significant atrophy only in the left MT gyrus compared to controls (Figure 3B). When directly compared, no significant differences emerged between the lvPPA-

GRN and the lvPPA-AD groups (Figure 3C). The detailed list of coordinates with local maximum atrophy for each comparison is provided in Table e-9.

PPA-*GRN* cases in the literature

In the literature, the frequency of PPA phenotypes in *GRN* carriers ranged from 12 to 38% according to cohort studies^{15,18,30–32} (Table e-10). Besides, the frequency of *GRN* mutation carriers within PPA cohorts ranged from 2% to 10%^{18,33–35} (Table e-11).

The descriptions of the 23 *GRN* cases with in-depth linguistic characterization are summarized in Table 3. Fourteen were reported up to 2011, the year of the definition of the current diagnostic criteria. They were diagnosed with PPA (n=4), PNFA (n=8), nfvPPA (n=1) or progressive anomia (n=1). It is noteworthy that the most recurrent linguistic deficits were impaired naming (13/14), reduced speech output (12/14), word-retrieval difficulties in spontaneous speech (11/14) and phonological errors (10/14). Frank agrammatism was seldom present, as well as AOS, which characterized four PNFA/nfvPPA cases.

Interestingly, when splitting the nine most recent cases described after 2011 according to their diagnoses, lvPPA was the most frequent variant (n=5/9) even if mild comprehension deficits emerged in two of them^{17,21}. The cause of which is possibly to be ascribed to increasing sentence complexity or latent semantic impairment. The diagnoses of nfvPPA mainly relied on the presence of agrammatism, whereas AOS was a rare occurrence (1/9). Overall, sentence-level processing deficits, when investigated, were a common finding among PPA-*GRN* cases from the literature.

DISCUSSION

The first evidence that FTD genes could produce PPA phenotypes was provided by Snowden *et al.*, (2006)¹³ and Mesulam *et al.* (2007)¹⁴ after discovery of the *GRN* gene. They described patients with “non fluent” aphasia who had phonological deficits, namely progressive anomia, without

overt motor speech impairment, and subsequent repetition and reading deficits. Circumscribed, profound anomia was remarkably predominant in one of them who received a diagnosis of “progressive anomia”¹⁹. A few *GRN* carriers with PNFA or nfvPPA have since been reported, but most were characterized based on the dichotomization of PPA in SD and PNFA, before the definition of the lvPPA. More recently, it emerged that not only agrammatism but also phonological/logopenic deficits may be predominant in some cases. However, only few underwent extensive linguistic characterization, and specific characteristics of genetic PPA have not yet been investigated in large series of patients. Here, we describe the linguistic, cognitive, and neuroimaging characteristics of 32 PPA patients who carried *GRN* mutations, representing a large cohort for a rare genetic disease, thus providing the first in-depth characterization of PPA-*GRN*.

The first important finding of the study is the high frequency of PPA amongst *GRN* carriers as high as 20%, or even 28% when considering all 45 PPA-*GRN* patients (including also those with insufficient clinical data to be in the study). This is in line with frequencies of PPA in other *GRN* cohorts varying from 12 to 38% (Table e-10). Some discrepancies between these studies might reflect distinct geographic origins and genetic backgrounds amongst populations, or different proportions of each PPA variant (especially lvPPA) within these cohorts. Some cohorts, as ours, may also be enriched in familial and genetic cases (Table e-11). Of note, only seven out of 330 (2%) *C9orf72* expansion carriers in the overall cohort received a diagnosis of PPA, not allowing to describe and compare them as a group. The markedly different frequency of *GRN* and *C9orf72* mutations in PPA patients suggests that gene-specific biological defects lead to distinct brain structures and language networks vulnerability, and highlights the importance of conducting separate studies of each genotype.

The logopenic-spectrum variant is the most frequent form of PPA-*GRN*

Another major finding is the high prevalence of logopenic variants, representing the main PPA phenotype associated with *GRN* mutations. The consensus criteria for lvPPA require impaired single-word retrieval in spontaneous speech and naming, impaired repetition of sentences/phrases with three of the following deficits: phonological errors, spared single-word comprehension, spared motor speech, and absence of frank agrammatism². All our lvPPA patients fit these criteria. Seven of them had no other linguistic deficits (“pure lvPPA”), whereas six (“lvPPA+”) had an obvious predominant logopenic deficit but a broader mild deficit in semantics, grammar, or articulation not fitting criteria for mixed PPA. Overall, these subtle variabilities in lvPPA phenotypes could be better gathered under the umbrella term “logopenic-spectrum variant”.

By itself, the former group, defining lvPPA in its strictest sense, encompassed 22% of the *GRN* carriers. This high prevalence was unexpected, as lvPPA typically results from amyloid pathology suggestive of AD⁴. Notwithstanding, recent studies have reported amyloid-negative lvPPA cases that could represent as much as 14% of lvPPA patients⁷ based on negative AD biomarkers in CSF¹¹, negative PiB-PET^{10,12,21}, or non-amyloid pathology at autopsy⁶⁻⁸. In the literature, no major linguistic differences distinguish amyloid-negative and amyloid-positive lvPPA, except for worse sentence repetition, naming and single-word comprehension deficits in amyloid-negative patients^{12,36}.

The coincidental association of *GRN* mutations with comorbid amyloid pathology responsible for lvPPA is unlikely in our patients, as AD biomarkers were negative for all patients for whom CSF was available (10/10, not available in three). A direct role of *GRN* mutations in the emergence of the phonological/logopenic deficit is much more likely. This is supported by the report of a number of *GRN* patients displaying predominant logopenic deficit^{16,34,35}, and by prior descriptions of six non-amyloid lvPPA patients, amongst whom three carried *GRN* mutations²¹. The frequency of logopenic-spectrum in our study is also concordant with a pathological study on four PPA-*GRN* patients, half of whom presented a logopenic variant¹⁷. Lastly, strong evidence linked amyloid-

negative lvPPA with TDP-43 pathology, mostly type A⁷, which is also the major pathological type underlying *GRN* mutations.

The diagnosis of lvPPA according to the consensus criteria remains challenging, partially due to the intrinsic difficulties in assessing key features and the possible overlap between variants. Most studies have demonstrated the good predictability of svPPA criteria, but the separation of lvPPA from nfvPPA is more elusive. The features defining lvPPA are still a matter of debate. Some groups have proposed adaptations to consensus criteria, suggesting the replacement of impaired repetition by “absence of definite grammar and comprehension impairment” as a core feature of lvPPA³⁷. Others have proposed less strict criteria, tolerating moderate impairment of single-word comprehension “as long as it doesn’t exceed that of complex sentence comprehension”³⁸. The importance of considering phonological errors amongst the main criteria has also been underlined³⁹. Finally, some studies showed that the most discriminative features to correctly classify patients were single-word comprehension deficit, agrammatism, impaired sentence repetition, and motor speech disorders^{6,10,29}.

The diagnostic complexity and criteria inconsistencies for lvPPA might possibly explain its unexpected frequency in our series, especially because the criteria were applied retrospectively for some patients (two lvPPAs) evaluated before 2004. However, this is unlikely to explain all our cases, and the application of the most discriminative features cited above also categorized most of these *GRN* patients as lvPPA, thus validating the robustness of the diagnoses. Additionally, our lvPPA-*GRN* patients showed significant GM atrophy in the left posterior MT gyrus, a part of the left temporo-parietal junction shown to be critically involved in phonological processing and verbal short-term memory, and predominantly altered in lvPPA⁴⁰⁻⁴³. Consistent with our neuroanatomical results, pathological studies demonstrated predominant TDP-43 inclusions in the left posterior temporal gyri and inferior parietal lobule in two lvPPA-*GRN* patients¹⁷. More generally, the posterior lateral temporal lobe appears to be a crucial area particularly vulnerable in

GRN disease, even at the earliest stages of the pathological process⁴⁴. The neuroimaging pattern in our patients was also comparable to that of lvPPA-AD in our study, except for additional atrophy in fronto-orbital areas. That likely mirrored the mild impairment in frontal functions in lvPPA-*GRN* patients, both of which are not unexpected in a cohort of *GRN* carriers.

Plasma progranulin dosage, predicting *GRN* mutations when low, has been routinely used by French centers since 2009 for all bvFTD and PPA patients, including lvPPA when AD biomarkers are negative. This provides another possible explanation for the high prevalence of lvPPA in our study. LvPPA is also possibly underdiagnosed because of the lack of molecular investigations in amyloid-negative lvPPA cases, and of detailed linguistic explorations in large *GRN* cohorts. Overall, our study confirms that different molecular and pathological processes may underlie the clinical and topographic syndrome of lvPPA, and provides strong evidence that *GRN* mutations may be involved in a part of amyloid-negative lvPPA. Genetic screening in cohorts of amyloid-negative lvPPA will be needed to confirm this hypothesis and, eventually, clarify their etiology.

Agrammatism prevails over AOS in nfvPPA-*GRN*

Two different forms of nfvPPA, dominated by agrammatism or AOS, have emerged from the description of their linguistic characteristics, patterns of atrophy, and underlying pathology^{20,45,46}. Prevailing AOS is associated with focal atrophy in premotor cortex and rather predictive of FTLT-TAU, whereas agrammatic patients had more widespread atrophy, extending to premotor, prefrontal, and temporo-parietal regions, and were more likely to harbor TDP-43 inclusions^{45,47}. The more diffuse pattern of atrophy evidenced in the latter group has been associated with more severe language deficits during disease progression and a worse outcome⁴⁷.

The relatively large number of patients in our study allowed to depict the most recurrent linguistic profile characterizing nfvPPA-*GRN*. Nearly all our *GRN* patients had frank agrammatism, whereas the phenotype dominated by AOS was rare in this study, as in the literature. This study thus

provides an additional piece of evidence for a clinico-pathological duality among nfvPPA, and for a privileged link between the agrammatic subtype of nfvPPA and TDP-43 pathology, which is the pathological substrate of *GRN* mutations.

Beyond the criteria: the mixed PPA-*GRN* phenotypes

Multiple levels of language elaboration (auditory-verbal short-term memory, grammar processing, semantic access, and, seldomly, semantic storage) may all be simultaneously altered in PPA-*GRN*. Anatomical regions associated with these functions include left posterior inferior frontal, anterior inferior parietal, temporo-polar, posterior superior, and MT cortices^{11,48}. The most prevalent linguistic deficits in our mixed PPA patients almost always included core features of lvPPA associated with moderate grammatical, word-comprehension deficits and deep/phonological dyslexia, similarly to some reported *GRN* carriers^{13,16,21,35}.

The multifaceted presentation of PPA phenotypes, particularly in their mixed forms, offers an interesting opportunity to consider the degenerative conditions associated with progranulin deficiency from a network perspective. According to the current model of language processing, a ventral stream involved in word meaning links the superior temporal gyrus to the middle/inferior temporal gyri, temporal pole, and inferior frontal cortices. A dorsal pathway involved in sound articulation connects the superior temporal gyrus with inferior parietal and frontal cortices. Our results and previous studies suggest that the temporal lobe and temporo-parietal junction are key regions in the *GRN*-mediated pathological process^{43,44}, and that both the dorsal and ventral language pathways may be altered to varying degrees in PPA-*GRN*. We can speculate that the resulting predominant phenotype largely depends on which parts of the network are affected and to what extent.

Diagnostic impact and recommendations for clinical practice

This study provides important information for clinical practice. Based on the literature and our results, we propose some recommendations for genetic testing according to the PPA variant. The remarkably high frequency of PPA patients with non-familial FTD in our series (up to 19%) indicates that genetic studies should not be limited to familial cases.

Overall, PPA is more often associated with *GRN* than with *C9orf72* mutations. We suggest measuring plasma progranulin levels in all patients with nfvPPA and those with amyloid-negative lvPPA (even without family history) before analysing the *GRN* gene when levels are decreased. Moreover, considering both the lvPPA+ and the mixed patients, an important proportion of our *GRN* cohort (14/32, 44%) escaped a strict classification, indicating that *GRN* mutations should also be primarily considered in patients displaying atypical/mixed PPA variants.

AOS is rarely associated with *GRN*, and generally predictive of FTLT-TAU pathology^{45,46}, supporting the *MAPT* gene analysis as the first indication in this phenotype, particularly in patients with family history of FTD. SvPPA is also rarely associated with *GRN* mutations and, more broadly, with FTD gene mutations.

CONCLUSION

This study contributes to a better description of the linguistic spectrum in a large cohort of patients with PPA related to *GRN* mutations, with major clinical impact due to upcoming *GRN*-targeted therapies. The heterogeneous phenotypes in our patients suggest *GRN* mutations may exert a noxious effect on distinct neocortical networks, with partial overlap in some key linguistic areas. Importantly, the most prevalent PPA-*GRN* phenotype determines logopenic/phonological deficits correlated with left posterior temporal atrophy. In clinical practice, this study highlights that *GRN*

should be investigated in the emerging group of logopenic variants with negative AD biomarkers, and emphasizes the usefulness of measuring plasma progranulin levels in this indication.

Our study had some limitations. Due to the rarity of genetically determined PPA, cases were recruited over a long time-lapse and required some data harmonization to compare linguistic and cognitive impairments. However, the rigorous evaluation and selection process of the patients ensured the reliability of the diagnoses and the classification of PPA variants. Conversely, our inclusion procedure, based on fulfillment of international criteria for PPA, may have prevented us from capturing milder and unclassifiable phenotypes in this study. Lastly, some subgroups such as svPPA were only presented in a descriptive way as they were too small to perform statistical analyses.

The prediction of the trajectory of neurodegenerative diseases, in particular PPA, at the individual level is still very challenging. Our study shows that mutations in *GRN* gene, all resulting in *GRN* deficiency, can lead to different PPA variants. It seems to indicate that the causal mechanism may be more complex than the gene alone, and still unknown patient-specific factors might interact with causal mutations, resulting in variable clinical phenotypes. Further studies, addressing the earliest disease stages in gene carriers, will likely provide insights into which factors affect the severity of the linguistic and extra-linguistic deficits, and preferentially drive the phenotype to PPA. More specifically, the study of genetic modifiers, especially those connected to language-learning disabilities, might clarify the biological determinants of selective lesion tropism for the language networks in patients displaying genetic PPA. Advances in these domains could enhance our understanding of the disease trajectory in FTL, provide new evidence supporting different degenerative pathways, link specific molecular dysfunctions with clinical phenotypes, and, finally, facilitate the correct classification of these still elusive cognitive phenotypes.

ACKNOWLEDGMENTS

We thank the DNA and cell bank of the ICM (ICM, Paris), Kathy Larcher (UF de Neurogénétique, Pitié-Salpêtrière Hospital, Paris), Sandrine Noël (UF de Neurogénétique, Pitié-Salpêtrière Hospital, Paris), and Isabelle David (UF de Neurogénétique, Pitié-Salpêtrière Hospital, Paris) for their technical assistance. The authors wish to thank Valerio Gargiulo for his support in the final editing of the manuscript.

Appendix 1: Authors

| Name | Location | Contribution |
|------------------------------|--|---|
| Dario Saracino, MD | Hôpital Pitié-Salpêtrière, Paris, FR | Designed and conceptualized the study; analyzed and interpreted the data; drafted the manuscript for intellectual content |
| Sophie Ferrieux | Hôpital Pitié-Salpêtrière, Paris, FR | Major role in the acquisition of data; analyzed the data |
| Marie Noguès-Lassaille | Hôpital Pitié-Salpêtrière, Paris, FR | Major role in the acquisition of data; analyzed the data |
| Marion Houot, MSc | Hôpital Pitié-Salpêtrière, Paris, FR | Analyzed the data |
| Aurélie Funkiewiez, PhD | Hôpital Pitié-Salpêtrière, Paris, FR | Major role in the acquisition of data; analyzed the data |
| Leila Sellami, MD | Hôpital Pitié-Salpêtrière, Paris, FR | Analyzed and interpreted the data; revised the manuscript for intellectual content |
| Vincent Deramecourt, MD, PhD | Lille University Hospital, Lille, FR | Major role in the acquisition of data; revised the manuscript for intellectual content |
| Florence Pasquier, MD, PhD | Lille University Hospital, Lille, FR | Major role in the acquisition of data; revised the manuscript for intellectual content |
| Philippe Couratier, MD, PhD | Limoges University Hospital, Limoges, FR | Major role in the acquisition of data; revised the manuscript for intellectual content |
| Jérémie Pariente, MD, PhD | Toulouse University Hospital, Toulouse, FR | Major role in the acquisition of data; revised the manuscript for intellectual content |
| Amandine Géraudie | Toulouse University Hospital, Toulouse, FR | Major role in the acquisition of data; revised the manuscript for intellectual content |
| Stéphane Epelbaum, MD, PhD | Hôpital Pitié-Salpêtrière, Paris, FR | Major role in the acquisition of data; revised the manuscript for intellectual content |
| David Wallon, MD, PhD | Rouen University Hospital, Rouen, FR | Major role in the acquisition of data; revised the manuscript for intellectual content |
| Didier Hannequin, MD, PhD | Rouen University Hospital, Rouen, FR | Major role in the acquisition of data; revised the manuscript for intellectual content |

| | | |
|--|---|--|
| Olivier Martinaud, MD, PhD | Caen University Hospital, Caen, FR | Major role in the acquisition of data; revised the manuscript for intellectual content |
| Fabienne Clot, PhD | Hôpital Pitié-Salpêtrière, Paris, FR | Analyzed the data; revised the manuscript for intellectual content |
| Agnès Camuzat, MSc | Hôpital Pitié-Salpêtrière, Paris, FR | Interpreted the data; revised the manuscript for intellectual content |
| Simona Bottani, MSc | Hôpital Pitié-Salpêtrière, Paris, FR | Analyzed the data; revised the manuscript for intellectual content |
| Daisy Rinaldi, PhD | Hôpital Pitié-Salpêtrière, Paris, FR | Major role in the acquisition of data; revised the manuscript for intellectual content |
| Sophie Auriacombe, MD | Bordeaux University Hospital, Bordeaux, FR | Major role in the acquisition of data; revised the manuscript for intellectual content |
| Marie Sarazin, MD, PhD | Hôpital Sainte Anne, Paris, FR | Major role in the acquisition of data; revised the manuscript for intellectual content |
| Mira Didic, MD, PhD | Aix-Marseille University Hospital, Marseille, FR | Major role in the acquisition of data; revised the manuscript for intellectual content |
| Claire Boutoleau-Brettonnière, MD, PhD | Nantes University Hospital, Nantes, FR | Major role in the acquisition of data; revised the manuscript for intellectual content |
| Christel Thauvin-Robinet, MD, PhD | Dijon-Bourgogne University Hospital, Dijon, FR | Major role in the acquisition of data; revised the manuscript for intellectual content |
| Julien Lagarde, MD | Hôpital Sainte Anne, Paris, FR | Major role in the acquisition of data; revised the manuscript for intellectual content |
| Carole Roué-Jagot, MD | Hôpital Sainte Anne, Paris, FR | Major role in the acquisition of data; revised the manuscript for intellectual content |
| François Sellal, MD, PhD | Strasbourg-Colmar University Hospital, Strasbourg, FR | Major role in the acquisition of data; revised the manuscript for intellectual content |
| Audrey Gabelle, MD, PhD | Montpellier University Hospital, Montpellier, FR | Major role in the acquisition of data; revised the manuscript for intellectual content |

| | | |
|------------------------------------|---|---|
| Frédérique Etcharry-Bouyx, MD, PhD | Angers University Hospital, Angers, FR | Major role in the acquisition of data; revised the manuscript for intellectual content |
| Alexandre Morin, MD | Hôpital Pitié-Salpêtrière, Paris, FR | Major role in the acquisition of data; revised the manuscript for intellectual content |
| Cinzia Coppola, MD, PhD | Naples University Hospital, Naples, IT | Revised the manuscript for intellectual content |
| Richard Levy, MD, PhD | Hôpital Pitié-Salpêtrière, Paris, FR | Revised the manuscript for intellectual content |
| Bruno Dubois, MD | Hôpital Pitié-Salpêtrière, Paris, FR | Revised the manuscript for intellectual content |
| Alexis Brice, MD, PhD | Hôpital Pitié-Salpêtrière, Paris, FR | Revised the manuscript for intellectual content |
| Olivier Colliot, PhD | Hôpital Pitié-Salpêtrière, Paris, FR | Interpreted the data; revised the manuscript for intellectual content |
| Maria Luisa Gorno-Tempini, MD, PhD | University of California, San Francisco, CA, US | Interpreted the data; revised the manuscript for intellectual content |
| Marc Teichmann, MD, PhD | Hôpital Pitié-Salpêtrière, Paris, FR | Revised the manuscript for intellectual content |
| Raffaella Migliaccio, MD, PhD | Hôpital Pitié-Salpêtrière, Paris, FR | Analyzed and interpreted the data; revised the manuscript for intellectual content |
| Isabelle Le Ber, MD, PhD | Hôpital Pitié-Salpêtrière, Paris, FR | Designed and conceptualized the study; analyzed and interpreted the data; drafted the manuscript for intellectual content |

Appendix 2: Co-investigators

| Name | Location | Role | Contribution |
|-------------------------------|--|-------------------|---------------------------------------|
| Serge Belliard, MD | Rennes University Hospital, FR | Site investigator | Coordinated communication among sites |
| Frédéric Blanc, MD | Hôpitaux Civils, Strasbourg, FR | Site investigator | Coordinated communication among sites |
| Mathieu Ceccaldi, MD, PhD | University Hospital La Timone, Marseille, FR | Site investigator | Coordinated communication among sites |
| Charles Duyckaerts, MD, PhD | Hôpital Pitié-Salpêtrière, Paris, FR | Site investigator | Coordinated neuropathology for site |
| Maité Formaglio, MD | Lyon University Hospital, Lyon, FR | Site investigator | Coordinated communication among sites |
| Véronique Golfier, MD | Rennes University Hospital, FR | Site investigator | Coordinated communication among sites |
| Lucette Lacomblez, MD | Hôpital Pitié-Salpêtrière, Paris, FR | Site investigator | Coordinated communication among sites |
| Bernard-François Michel, MD | Hôpital Sainte-Marguerite, Marseille, FR | Site investigator | Coordinated communication among sites |
| Catherine Thomas-Anterion, MD | Plein-Ciel Hospital, Lyon, FR | Site investigator | Coordinated communication among sites |
| Martine Vercelletto, MD | Nantes University Hospital, Nantes, FR | Site investigator | Coordinated communication among sites |

REFERENCES

1. Mesulam M-M. Primary progressive aphasia. *Ann Neurol*. 2001;49:425–432.
2. Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. *Neurology*. 2011;76:1006–1014.
3. Gorno-Tempini ML, Dronkers NF, Rankin KP, et al. Cognition and anatomy in three variants of primary progressive aphasia. *Ann Neurol*. 2004;55:335–346.
4. Mesulam M, Wicklund A, Johnson N, et al. Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. *Ann Neurol*. 2008;63:709–719.
5. Spinelli EG, Mandelli ML, Miller ZA, et al. Typical and atypical pathology in primary progressive aphasia variants. *Annals of Neurology*. 2017;81:430–443.
6. Mesulam M-M, Weintraub S, Rogalski EJ, Wieneke C, Geula C, Bigio EH. Asymmetry and heterogeneity of Alzheimer's and frontotemporal pathology in primary progressive aphasia. *Brain*. 2014;137:1176–1192.
7. Bergeron D, Gorno-Tempini ML, Rabinovici GD, et al. Prevalence of amyloid- β pathology in distinct variants of primary progressive aphasia. *Annals of Neurology*. 2018;84:729–740.
8. Chare L, Hodges JR, Leyton CE, et al. New criteria for frontotemporal dementia syndromes: clinical and pathological diagnostic implications. *Journal of Neurology, Neurosurgery & Psychiatry*. 2014;85:865–870.
9. Hu WT, McMillan C, Libon D, et al. Multimodal predictors for Alzheimer disease in nonfluent primary progressive aphasia. *Neurology*. 2010;75:595–602.
10. Leyton CE, Villemagne VL, Savage S, et al. Subtypes of progressive aphasia: application of the international consensus criteria and validation using β -amyloid imaging. *Brain*. 2011;134:3030–3043.
11. Teichmann M, Kas A, Boutet C, et al. Deciphering logopenic primary progressive aphasia: a clinical, imaging and biomarker investigation. *Brain*. 2013;136:3474–3488.
12. Santos-Santos MA, Rabinovici GD, Iaccarino L, et al. Rates of Amyloid Imaging Positivity in Patients With Primary Progressive Aphasia. *JAMA Neurology*. 2018;75:342.
13. Snowden JS, Pickering-Brown SM, Mackenzie IR, et al. Progranulin gene mutations associated with frontotemporal dementia and progressive non-fluent aphasia. *Brain*. 2006;129:3091–3102.
14. Mesulam M, Johnson N, Krefft TA, et al. Progranulin Mutations in Primary Progressive Aphasia. *Arch Neurol*. 2007;64:43–47.
15. Le Ber I, Camuzat A, Hannequin D, et al. Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study. *Brain*. 2008;131:732–746.
16. Rohrer JD, Crutch SJ, Warrington EK, Warren JD. Progranulin-associated primary progressive aphasia: A distinct phenotype? *Neuropsychologia*. 2010;48:288–297.
17. Kim G, Ahmadian SS, Peterson M, et al. Asymmetric pathology in primary progressive aphasia with progranulin mutations and TDP inclusions. *Neurology*. 2016;86:627–636.
18. Le Ber I, Guillot-Noel L, Hannequin D, et al. C9ORF72 Repeat Expansions in the Frontotemporal Dementias

Spectrum of Diseases: A Flow-chart for Genetic Testing. *JAD*. 2013;34:485–499.

19. Snowden JS, Pickering-Brown SM, du Plessis D, et al. Progressive Anomia Revisited: Focal Degeneration Associated with Progranulin Gene Mutation. *Neurocase*. 2007;13:366–377.
20. Deramecourt V, Lebert F, Debachy B, et al. Prediction of pathology in primary progressive language and speech disorders. *Neurology*. 2010;74:42–49.
21. Josephs KA, Duffy JR, Strand EA, et al. Progranulin-associated PiB-negative logopenic primary progressive aphasia. *Journal of Neurology*. 2014;261:604–614.
22. Le Ber I, Guedj E, Verpillat P, et al. Demographic, neurological and behavioural characteristics and brain perfusion SPECT in frontal variant of frontotemporal dementia. *Brain*. 2006;129:3051–3065.
23. Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. *Brain*. 2011;134:2456–2477.
24. Mazaux J, Orgogozo J. HDAE (BDAE): Echelle d'évaluation de l'aphasie. Paris: ECPA (Editions du Centre de Psychologie Appliquée); 1982.
25. Nespoulos J, Lecours A, Lafond D, et al. Protocole Montréal-Toulouse d'examen linguistique de l'aphasie MT-86. Isbergues: Ortho Edition; 1992.
26. Deloche G, Hannequin D. DO 80: Epreuve de dénomination orale d'image. Paris: ECPA (Editions du Centre de Psychologie Appliquée); 1997.
27. Godefroy O, GREFEX. Fonctions exécutives et pathologies neurologiques et psychiatriques. Evaluation en pratique clinique. Marseille: Solal; 2008.
28. Merck C, Charnallet A, Auriacombe S, et al. La batterie d'évaluation des connaissances sémantiques du GRECO (BECS-GRECO) □: validation et données normatives. *Revue de neuropsychologie*. 2011;3:235.
29. Marshall CR, Hardy CJD, Volkmer A, et al. Primary progressive aphasia: a clinical approach. *J Neurol*. 2018;265:1474–1490.
30. Chen-Plotkin AS, Martinez-Lage M, Sleiman PMA, et al. Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration. *Arch Neurol*. 2011;68:488–497.
31. Van Mossevelde S, van der Zee J, Gijssels I, et al. Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort. *Brain*. 2016;139:452–467.
32. Moore KM, Nicholas J, Grossman M, et al. Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. *Lancet Neurol*. 2020;19:145–156.
33. Gil-Navarro S, Lladó A, Rami L, et al. Neuroimaging and Biochemical Markers in the Three Variants of Primary Progressive Aphasia. *Dementia and Geriatric Cognitive Disorders*. 2013;35:106–117.
34. Flanagan EP, Baker MC, Perkerson RB, et al. Dominant Frontotemporal Dementia Mutations in 140 Cases of Primary Progressive Aphasia and Speech Apraxia. *Dementia and Geriatric Cognitive Disorders*. 2015;39:281–286.
35. Ramos EM, Dokuru DR, Van Berlo V, et al. Genetic screen in a large series of patients with primary progressive aphasia. *Alzheimer's & Dementia*. 2019;15:553–560.

36. Whitwell JL, Duffy JR, Strand EA, et al. Clinical and neuroimaging biomarkers of amyloid-negative logopenic primary progressive aphasia. *Brain and Language*. 2015;142:45–53.
37. Mesulam M-M, Weintraub S. Is it time to revisit the classification guidelines for primary progressive aphasia? *Neurology*. 2014;82:1108–1109.
38. Botha H, Duffy JR, Whitwell JL, et al. Classification and clinicoradiologic features of primary progressive aphasia (PPA) and apraxia of speech. *Cortex*. 2015;69:220–236.
39. Leyton CE, Ballard KJ, Piguet O, Hodges JR. Phonologic errors as a clinical marker of the logopenic variant of PPA. *Neurology*. 2014;82:1620–1627.
40. Gorno-Tempini ML, Brambati SM, Ginex V, et al. The logopenic/phonological variant of primary progressive aphasia. *Neurology*. 2008;71:1227–1234.
41. Rohrer JD, Caso F, Mahoney C, et al. Patterns of longitudinal brain atrophy in the logopenic variant of primary progressive aphasia. *Brain and Language*. 2013;127:121–126.
42. Rogalski E, Cobia D, Martersteck A, et al. Asymmetry of cortical decline in subtypes of primary progressive aphasia. *Neurology*. 2014;83:1184–1191.
43. Bonakdarpour B, Hurley RS, Wang AR, et al. Perturbations of language network connectivity in primary progressive aphasia. *Cortex*. Epub 2019.:S0010-9452(19)30298-9.
44. Whitwell JL, Weigand SD, Boeve BF, et al. Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. *Brain*. 2012;135:794–806.
45. Josephs KA, Duffy J. R., Strand E. A., et al. Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. *Brain*. 2006;129:1385–1398.
46. Rohrer JD, Rossor MN, Warren JD. Syndromes of nonfluent primary progressive aphasia: A clinical and neurolinguistic analysis. *Neurology*. 2010;75:603–610.
47. Tetzloff KA, Duffy JR, Clark HM, et al. Progressive agrammatic aphasia without apraxia of speech as a distinct syndrome. *Brain*. 2019;142:2466–2482.
48. Rohrer JD, Ridgway GR, Crutch SJ, et al. Progressive logopenic/phonological aphasia: Erosion of the language network. *NeuroImage*. 2010;49:984–993.
49. Krefft TA, Graff-Radford NR, Dickson DW, Baker M, Castellani RJ. Familial primary progressive aphasia. *Alzheimer Dis Assoc Disord*. 2003;17:106–112.
50. Beck J, Rohrer JD, Campbell T, et al. A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series. *Brain*. 2008;131:706–720.
51. Cerami C, Marcone A, Galimberti D, Villa C, Scarpini E, Cappa SF. From Genotype to Phenotype: Two Cases of Genetic Frontotemporal Lobar Degeneration with Premorbid Bipolar Disorder. *JAD*. 2011;27:791–797.
52. Caso F, Agosta F, Magnani G, et al. Clinical and MRI correlates of disease progression in a case of nonfluent/agrammatic variant of primary progressive aphasia due to progranulin (GRN) Cys157LysfsX97 mutation. *Journal of the Neurological Sciences*. 2014;342:167–172.

FIGURE LEGENDS

Figure 1. Flow-chart of the inclusion process. AD: Alzheimer's disease; ALS: amyotrophic lateral sclerosis; FTD: frontotemporal dementia; PPA: primary progressive aphasia.

Figure 2. Schematic description of the PPA-GRN cohort. A: number of patients diagnosed with each of the clinical variants. B: distribution of the cohort with respect to the linguistic deficits (right). Each patient is represented by a dot, whose position mirrors the predominant linguistic deficits. LvPPA: logopenic variant of PPA; nfvPPA: non-fluent/agrammatic variant of PPA; PPA: primary progressive aphasia; svPPA: semantic variant of PPA.

Figure 3. VBM analyses in lvPPA patients. A: comparison between lvPPA-GRN and controls; two main clusters of atrophy are present at the level of the left middle temporal gyrus and the left posterior orbital gyrus. B: comparison between lvPPA-AD and controls; isolated cluster of atrophy at the level of the left middle temporal gyrus. C: comparison between lvPPA-GRN and lvPPA-AD; no significant differences between the two groups of patients were found. The color bar refers to the T values (Table e-9). LvPPA-AD: logopenic variant of primary progressive aphasia associated with Alzheimer's disease; lvPPA-GRN: logopenic variant of primary progressive aphasia associated with GRN mutations; VBM: voxel-based morphometry.

| | All patients | lvPPA | nfvPPA | svPPA | mixed PPA |
|---|--------------------|--------------------|--------------------|-------------------|--------------------|
| Number of patients | 32 | 13 (41%) | 9 (28%) | 2 (6%) | 8 (25%) |
| Demographic data | | | | | |
| Gender (F/M) | 20/12 | 8/5 | 7/2 | 1/1 | 4/4 |
| Handedness (R/L/Adx), n | 29/2/1 | 10/2/1 | 9/0/0 | 2/0/0 | 8/0/0 |
| Family history, n ^a | 26 (81%) | 10 (77%) | 9 (100%) | 2 (100%) | 5 (63%) |
| Education level, y | 9.0 [8.8, 13.3] | 9.0 [6.0, 15.0] | 9.0 [9.0, 12.0] | 7.0 [6.0, 8.0] | 10.5 [9.0, 11.5] |
| Age at onset, y | 62.0 [59.0, 63.3] | 62.0 [59.0, 63.0] | 62.0 [56.0, 63.0] | 63.5 [60.3, 66.8] | 63.0 [61.5, 64.8] |
| Age at first evaluation, y | 64.0 [60.0, 66.0] | 63.0 [62.0, 65.0] | 63.0 [58.0, 65.0] | 66.0 [63.0, 69.0] | 65.0 [63.3, 66.8] |
| Disease duration at first evaluation, y | 2.0 [1.5, 2.5] | 1.5 [1.5, 2.5] | 1.5 [1.0, 2.0] | 2.8 [2.6, 2.9] | 2.2 [1.9, 2.5] |
| Speech and language assessment | | | | | |
| Global Aphasia Severity score (/5) ^b | 3.0 [2.0, 3.0] | 3.0 [2.3, 3.0] | 3.0 [3.0, 4.0] | 1.0 [1.0, 1.0] | 3.0 [2.0, 3.0] |
| Agrammatism (discrete to severe), n ^c | 14 (44%) | 0 | 8 (89%) | 0 | 6 (75%) |
| Semantic fluency in 2 minutes | 10 [5, 16] | 11 [6, 18] | 13 [9, 16] | 4 [2, 6] | 5 [4, 11] |
| Phonological (F) fluency in 2 minutes | 5 [2, 9] | 9 [2, 10] | 4 [3, 7] | 3 [1, 4] | 7 [5, 7] |
| Confrontation naming, % | 79 [50, 91] | 76 [59, 89] | 88 [83, 94] | 1 [1, 1] | 64 [25, 86] |
| Oral single-word comprehension, n ^c | 9 (28%) | 3 (23%) | 1 (11%) | 2 (100%) | 3 (38%) |
| Oral sentence comprehension, % | 66 [34, 82] | 77 [53, 86] | 69 [66, 88] | 19 [10, 29] | 33 [16, 67] |
| Repetition of sentences, % | 56 [50, 69] | 50 [38, 69] | 63 [56, 100] | 50 [50, 50] | 31 [0, 69] |
| Written sentence comprehension, % | 77 [63, 85] | 74 [70, 80] | 68 [43, 89] | 38 [30, 46] | 80 [77, 85] |
| Disease progression | | | | | |
| Median disease duration at death, y (n of deceased) | 7.5 [6.8, 8.0] (8) | 7.5 [7.3, 7.8] (2) | 6.5 [5.9, 7.3] (4) | - (0) | 8.5 [8.3, 8.8] (2) |
| Frontal lobe dysfunction, n | 32 (100%) | 13 (100%) | 9 (100%) | 2 (100%) | 8 (100%) |
| Executive dysfunction, n | 31 (97%) | 13 (100%) | 8 (89%) | 2 (100%) | 8 (100%) |
| And/or behavioral symptoms, n | 18 (56%) | 8 (62%) | 2 (22%) | 2 (100%) | 6 (75%) |
| Amnesic syndrome, n | 12 (38%) | 6 (46%) | 2 (22%) | 2 (100%) | 2 (25%) |

| | | | | | |
|---------------------------------------|----------|---------|---------|---------|---------|
| Parietal syndrome, n | 18 (56%) | 8 (62%) | 5 (56%) | 1 (50%) | 4 (50%) |
| Parkinsonism, n | 11 (34%) | 3 (23%) | 5 (56%) | 0 | 3 (38%) |
| Psychiatric disorders, n ^d | 5 (16%) | 1 (8%) | 1 (11%) | 1 (50%) | 2 (25%) |

Table 1. Demographic, linguistic and clinical characteristics of PPA patients carrying *GRN* mutations at first evaluation. Numbers are presented for categorical measures, with percentages in parentheses. Medians are presented for numerical measures, with first and third quartiles within brackets. ^aFamily history of FTLN spectrum disorders. ^bAphasia severity rating score evaluates the global severity of impairment of spontaneous speech and conversation following BDAE recommendations. ^cNumber (and percentage) of patients with impaired performance. ^dDelusions, depression or bipolar disorder. Adx: ambidextrous; F: female; FTLN: frontotemporal lobar degeneration; L: left-handed; lvPPA: logopenic variant of PPA; M: male; nfvPPA: non-fluent/agrammatic variant of PPA; PPA: primary progressive aphasia; R: right-handed; svPPA: semantic variant of PPA; y: years.

| | All patients | lvPPA | nfvPPA | svPPA | mixed PPA |
|---------------------------------|----------------------|----------------------|----------------------|-------------------|----------------------|
| MMSE (/30) | 20.0 [15.0, 24.5] | 20.5 [15.8, 24.8] | 23.0 [19.0, 25.0] | 9.5 [7.3, 11.8] | 16.5 [11.0, 22.8] |
| MDRS (/144) | 110.0 [91.5, 115.3] | 112.5 [102.2, 115.2] | 113.0 [109.0, 121.0] | 72.0 | 102.0 [77.0, 108.0] |
| Attention (/37) | 33.5 [32.0, 34.8] | 33.0 [32.0, 35.0] | 34.0 [34.0, 34.0] | 30.0 | 32.0 [32.0, 35.0] |
| Initiation (/37) | 23.0 [15.8, 30.3] | 26.0 [18.0, 33.0] | 28.0 [25.5, 29.5] | 9.0 | 21.0 [13.0, 23.0] |
| Construction (/6) ^a | 4 (29%) | 0 | 2 (67%) | 1 (100%) | 1 (20%) |
| Conceptualization (/39) | 26.5 [21.0, 30.5] | 29.0 [29.0, 31.0] | 27.0 [25.5, 32.0] | 19.0 | 25.0 [15.0, 26.0] |
| Memory (/25) | 16.5 [11.3, 19.0] | 19.0 [15.0, 25.0] | 19.0 [17.5, 21.5] | 9.0 | 12.0 [11.0, 17.0] |
| FAB (/18) | 10.5 [7.8, 13.0] | 12.0 [8.5, 13.5] | 11.0 [9.5, 14.8] | 3.5 [2.3, 4.8] | 8.5 [7.0, 12.3] |
| Forward digit span | 4.0 [3.0, 5.0] | 4.0 [3.0, 4.0] | 5.0 [3.0, 5.5] | 5.0 [4.5, 5.5] | 4.0 [3.0, 4.3] |
| Backward digit span | 3.0 [2.0, 3.0] | 3.0 [2.0, 3.0] | 3.0 [3.0, 3.0] | 1.0 [1.0, 1.0] | 2.5 [2.0, 3.0] |
| TMT-A | 62.0 [54.0, 74.0] | 62.0 [48.0, 73.0] | 61.5 [53.5, 65.0] | na | 65.0 [59.5, 78.5] |
| TMT-B | 263.0 [180.5, 329.5] | 188.0 [178.2, 245.0] | 263.0 [186.0, 313.0] | na | 439.5 [372.8, 506.2] |
| TMT(B-A) | 190.0 [122.5, 237.5] | 132.5 [122.2, 178.0] | 201.0 [139.5, 251.5] | na | 380.0 [310.5, 449.5] |
| FCSRT: free recall (/48) | 21.0 [14.3, 26.8] | 23.5 [19.5, 30.0] | 21.0 [16.0, 26.0] | na | 12 [8.0, 13.0] |
| FCSRT: total recall (/48) | 39.0 [27.0, 46.0] | 40.0 [34.3, 46.8] | 43.0 [40.0, 46.0] | na | 25.0 [24.0, 31.5] |
| FCSRT: sensitivity to cueing, % | 75 [43, 92] | 71 [42, 93] | 85 [77, 92] | na | 43 [40, 57] |
| ROCF recall (/36) | 15.0 [12.0, 19.0] | 17.0 [11.8, 19.0] | 12.0 [12.0, 14.3] | 15.0 [15.0, 15.0] | 15.8 [14.5, 17.4] |
| ROCF copy (/36) | 33.0 [28.5, 36.0] | 31.0 [27.3, 35.0] | 33.0 [31.5, 35.3] | 33.0 [32.0, 34.0] | 36.0 [30.0, 36.0] |
| Ideo-motor apraxia (/63) | 57.5 [46.0, 60.3] | 58.0 [55.0, 60.0] | 58.0 [34.0, 59.0] | 33.0 [30.0, 36.0] | 47.0 [43.0, 63.0] |

Table 2. Cognitive characteristics of PPA patients carrying *GRN* mutations at first evaluation. Results are expressed as the median values, with the first and third quartiles within

brackets, for numerical measures. Maximal scores of each test are indicated in parentheses.

^aAbsolute count and percentage (in parentheses) of patients with impaired performance, with respect to the total number of subjects who underwent the test. FAB: Frontal Assessment Battery; FCSRT: Free and Cued Selective Reminding Test; lvPPA: logopenic variant of PPA; MDRS: Mattis Dementia Rating Scale; MMSE: Mini Mental Status Examination; na: not available or unable to test; nfvPPA: non-fluent/agrammatic variant of PPA; PPA: primary progressive aphasia; ROCF: Rey-Osterrieth Complex Figure; svPPA: semantic variant of PPA; TMT: Trail Making Test.

| | Krefft <i>et al.</i> , 2003 ⁴⁹ Mesulam <i>et al.</i> , 2007 ¹⁴ | | | Snowden <i>et al.</i> , 2006 ¹³ | | Snowden <i>et al.</i> , 2007 ¹⁹ | Beck <i>et al.</i> , 2008 ⁵⁰ | | | | | Rohrer <i>et al.</i> , 2010 ¹⁶ |
|---|---|------------|------------|---|----------------|--|---|---------------|----------------|-------|----------------|---|
| Patient | PPA 1:A | PPA 1:C | PPA 1:D | III-5 | III-1 | N. | 240-4 | 255-9 | 255- 10 | 430-2 | 431-3 | SC |
| Diagnosis | PPA | PPA | PPA | PNFA | PNFA | Progressive anomia | PNF A | PNFA / CBS | PNFA | PNFA | PNFA /SD | PPA |
| AAO (y) | 60 | 61 | 65 | 63 | 65 | 66 | na | na | na | na | na | 62 |
| DD at evaluation (y) | 5 | 1 | 3 | 2 | 2 | 3 | 4 | 1 | 3 | 4 | 1 | 3 |
| Reduced speech output | - | + | + | + | + | + | + | + | + | + | - | + |
| Impaired naming | + | + | + | + | + | + | - | + | + | + | + | + |
| Word-retrieval difficulties | + | + | + | + | + | + | - | - | + | - | + | + |
| Impaired word repetition | - | na | na | + ^a | + ^a | - | na | na | na | na | na | + |
| Impaired sentences repetition | - | na | na | + ^a | + ^a | - | na | na | na | na | na | + |
| Phonological paraphasias | - | - | + | + | + | - | + | - | + | + | + | + |
| Agrammatism | - | - | - | - | + | (+) | - | - | - | - | - | + |
| AOS | - | - | - | + ^b | - | - | - ^c | + | - ^c | + | - | - |
| Impaired sentences comprehension | - | + | + | - | + | - | na | na | na | na | na | + ^e |
| Impaired word comprehension | + | + | na | - | - | - | na | - | - | + | - | + |
| Impaired object knowledge | - | - | na | - | - | - | - | - | - | - | + | - |
| Impaired reading | na | + | na | + ^a | - | - | - | + | - | + | + ^d | + |
| Verbal/semantic paraphasias | + | + | + | (+) | - | - | na | na | na | na | na | + |

Table 3. Description of previously published PPA cases with *GRN* mutations (continues at next page).


| | Derame court <i>et al.</i> , 2010 ²⁰ | Cerami <i>et al.</i> , 2011 ⁵¹ | Caso <i>et al.</i> , 2014 ⁵² | Josephs <i>et al.</i> , 2014 ²¹ | | | Mesulam <i>et al.</i> , 2007 ¹⁴ Mesulam <i>et al.</i> , 2014 ⁶ Kim <i>et al.</i> , 2016 ¹⁷ | | | | |
|-------------------------------------|---|---|--|--|----------------|-------|---|--------|--------|-------|-------------------|
| Patient | 7 | 2 | SC | 1 | 2 | 3 | PPA3: A | 1 | P22/ 2 | 3 | PPA3:B /P21/ 4 |
| Diagnosis | nfvPPA | PNFA | nfvPPA | lvPPA | lvPPA | lvPPA | PPA | nfvPPA | nfvPPA | lvPPA | lvPPA |
| AAO (y) | 60 | na | 60 | 56 | 61 | 56 | 65 | 56 | 50 | 53 | 62 |
| DD at evaluation (y) | 1 | 1 | 3 | 2 | 3 | 2 | 1 | 2 (5†) | 2 (6†) | (8†) | 2 (6†) |
| Reduced speech output | + | + | + | + | + | + | + | + | + | + | + |
| Impaired naming | + | + | + | - | + | + | + | - | - | + | + |
| Word-retrieval difficulties | + | + | + | + | + | + | + | + | - | + | + |
| Impaired word repetition | - | - | (+)† | na | na | na | - | na | na | na | - |
| Impaired sentences repetition | + | + | + | + | + | + | + ^c | na | (+) | na | na |
| Phonological paraphasias | + | + | + | + | + | + | + | na | + | na | - |
| Agrammatism | + | + | + | - | - | - | + | + | + | - | - |
| AOS | (+) | - ^c | + | - | - | - | - | - | - | - | - |
| Impaired sentences comprehension | + | + | + | + ^g | + ^g | + | + ^g | na | (+) | na | - ^h |
| Impaired word comprehension | - | - | - | - | - | + | - | na | - | na | - ^h |
| Impaired object knowledge | - | na | na | - | - | + | - | na | na | na | - |
| Impaired reading | - | + | na | - | - | + | + ^g | na | na | na | na |
| Verbal/semantic paraphasias | + | na | - | na | na | na | - | na | - | na | - |



Table 3. Description of previously published PPA cases with GRN mutations (continued).

^aPhonological errors. ^bStuttering. ^cBuccofacial apraxia. ^dPhonological dyslexia. ^eWorse for passive, reversible and complex sentences. ^fWith word length effect. ^gFor complex sentences. ^hIntermittent comprehension deficits. AAO: age at onset; AOS: apraxia of speech; CBS: corticobasal syndrome; DD: disease duration; lvPPA: logopenic variant of PPA; na: not available; nfvPPA: non-fluent/agrammatic variant of PPA; PNFA: progressive non-fluent


aphasia; PPA: primary progressive aphasia; SC: single case; SD: semantic dementia; y: years.

(+): occasional or mild difficulties. (†): disease duration at death.







A – IvPPA-GRN vs Controls



B – IvPPA-AD vs Controls



C – IvPPA-GRN vs IvPPA-AD

